Q-omics provides the consensus-scored RAB5A profile across patient tissues and cancer cell-line models. RAB5A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RAB5A is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, RAB5A RNA expression shows 19,968 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, LIHC, and ACC as cancer lineages where RAB5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB5A survival associations across molecular data types. RAB5A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB5A RNA expression–survival associations across cancer types. High RAB5A expression shows unfavorable associations in MESO, LUSC, ACC, PAAD and SCLC, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for RAB5A RNA expression.
This table summarizes RAB5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB5A shows lower tumor expression in KIRC, THCA, KICH and LUSC and higher tumor expression in LIHC and BLCA. The LIHC box plot shows higher RAB5A RNA expression in tumor versus normal tissue (log2 FC = +0.544, t-test p < 0.001).
This table shows molecular features associated with RAB5A in patient tissues and cancer cell lines. In patient samples, RAB5A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
